Frontiers in oncology · 2026
Characterization of JAK2V617F and the JAK2 46/1 germline haplotype in myeloproliferative neoplasms in a Saudi Arabian cohort: a case-based analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mutrib Nouf, Alqarni Sana, Peer-Zada Abdul Ali, Samman Manar, Fatima Sabiha, Arjumand Sadia, Aldahshan Hala, Alharbi Khalid K, AlRashed May M
Аннотация
BACKGROUND: JAK2V617F is an important mutation associated with myeloproliferative neoplasms (MPNs). The germline JAK2 46/1 haplotype is an established low-penetrance predisposition factor for MPNs across multiple ethnicities. This study aimed to characterize JAK2V617F mutation prevalence and JAK2 46/1 haplotype distribution in a Saudi Arabian MPN cohort.
METHODS: A retrospective cohort study was conducted at King Fahad Medical City, Riyadh, Saudi Arabia. A total of 130 participants (98 MPN patients and 32 non-MPN controls) were enrolled between January 2018 and December 2019. JAK2V617F mutation status was determined by allele-specific TaqMan qPCR. SNPs rs12343867 and rs10974900 were genotyped using validated TaqMan SNP assays to define haplotype carrier status.
RESULTS: JAK2V617F was detected in 13.1% of patients (n=17; 9 females, 8 males), with no statistically significant sex-based difference in mutation frequency. At rs12343867, the aggregate 46/1 haplotype carrier frequency was 80.7% (homozygous TT: 51.5%; heterozygous CT: 29.2%). By MPN subtype, TT homozygosity was most prevalent in ET (56.3%). By MPN subtype, the CC genotype predominated in ET (57.8%), PV (50.0%), PMF (75.0%), and non-MPN controls (54.8%).
CONCLUSIONS: This is the first study to simultaneously characterize JAK2V617F and the germline JAK2 46/1 haplotype in a Saudi Arabian MPN cohort. The elevated haplotype carrier frequency supports an inherited predisposition to MPN in this population and positions the JAK2 46/1 haplotype as a candidate supplementary biomarker for risk stratification. Prospective, multi-centre studies incorporating comprehensive driver mutation profiling and population-matched healthy controls are warranted.
METHODS: A retrospective cohort study was conducted at King Fahad Medical City, Riyadh, Saudi Arabia. A total of 130 participants (98 MPN patients and 32 non-MPN controls) were enrolled between January 2018 and December 2019. JAK2V617F mutation status was determined by allele-specific TaqMan qPCR. SNPs rs12343867 and rs10974900 were genotyped using validated TaqMan SNP assays to define haplotype carrier status.
RESULTS: JAK2V617F was detected in 13.1% of patients (n=17; 9 females, 8 males), with no statistically significant sex-based difference in mutation frequency. At rs12343867, the aggregate 46/1 haplotype carrier frequency was 80.7% (homozygous TT: 51.5%; heterozygous CT: 29.2%). By MPN subtype, TT homozygosity was most prevalent in ET (56.3%). By MPN subtype, the CC genotype predominated in ET (57.8%), PV (50.0%), PMF (75.0%), and non-MPN controls (54.8%).
CONCLUSIONS: This is the first study to simultaneously characterize JAK2V617F and the germline JAK2 46/1 haplotype in a Saudi Arabian MPN cohort. The elevated haplotype carrier frequency supports an inherited predisposition to MPN in this population and positions the JAK2 46/1 haplotype as a candidate supplementary biomarker for risk stratification. Prospective, multi-centre studies incorporating comprehensive driver mutation profiling and population-matched healthy controls are warranted.